Patent ID: 8951725
Filing Date: 2015-02-10
Classification: C12Q

Abstract:
1. A method of determining prognosis of lung cancer in a human patient, the method comprising: (a) obtaining a biological sample comprising malignant lung cells from a human patient classified as having Stage IB, IIA, or IIB non-small cell lung cancer; (b) contacting the biological sample with a set of chromosomal probes comprising at least two probes selected from a group consisting of a chromosome 5p15.2 locus specific probe, a chromosome 8q24 locus specific probe that includes the C-MYC gene, a chromosome 6 enumeration probe, and a chromosome 7p12 locus specific probe that includes the EGFR gene under conditions sufficient to enable hybridization of probes in the set to chromosomes in the sample, if any, wherein each of the chromosomal probes is directly labeled with a fluorescent label that can be separately detected; (c) detecting in a population of said malignant lung cells a hybridization pattern of the set of chromosomal probes, wherein the hybridization pattern indicates the percentage of cells in which the difference between the number of probe signals in the locus with the greatest number of probes and the number of probe signals in the locus with the lowest number of probe signals is greater than three; (d) providing a prognosis of lung cancer in the patient based upon the hybridization pattern detected in step (c), wherein said percentage of cells is at least 42% and the prognosis is an increased time to recurrence (TTR) after surgical resection, or said percentage of cells is less than 42% and the prognosis is a decreased TTR after surgical resection, and (e) administering adjuvant chemotherapy post-surgery or administering neoadjuvant chemotherapy before surgery when the percentage of cells in step (c) is less than 42%.